Home > Boards > US OTC > Biotechs >

Amarantus Bioscience Holdings Inc. (AMBS)

Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: joboggi, zoomboom, JJAAMMAANN, Rosym
Search This Board:
Last Post: 2/10/2016 10:13:13 AM - Followers: 743 - Board type: Free - Posts Today: 11


(AMBS) Amarantus BioScience Holdings, Inc. 

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2 ready Parkinsons Levadopa induced Dyskinesia.

The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a
 diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.  (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test. 
For further information, please visit, or connect with the company in FacebookTwitter, LinkedIn & Google+






Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
February 10, 2016

Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
February 9, 2016

Burn Care 3.0: Tissue-Engineered Skin is Regenerative Medicine in Action
February 8, 2016
Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa

February 5, 2016
Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
February 3, 2016 
Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease

Patent issuance will provide intellectual property protection in China for protein therapy, gene therapy and cell therapy applications of MANF
January 29, 2016
Amarantus Announces $1M Investment
January 27, 2016
Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics

January 19, 2016
Amarantus to Present at ICV Sonoma Event
January 15, 2016
Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference
January 11, 2016
Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi
DECEMBER 29, 2015
Amarantus Provides Update on cGMP Manufacturing Validation for the Engineered Skin Substitute (ESS) Program
DECEMBER 22, 2015
More News

Bio-engineering skin to treat severe burns



SNNLive with Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS) - December 2015


ESS Patients: Dr. Ahrenholz Interview Part 1 

ESS vs the Competition: Dr. Ahrenholz Interview Part 2

The Need for ESS: Dr. Ahrenholz Interview Part 3

 Predicting Alzheimer's before it      starts Published on Apr. 8, 2015
 SNNLive - Amarantus BioScience
Holdings, Inc. - 
Dec. 12, 2014

Developing an Accurate Test for Multiple Sclerosis - Mar. 5, 2014

                                                               Contact Information

Amarantus BioScience Holdings, Inc.
655 Montgomery Street
Suite 900
San Francisco, CA 94111


c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva

Phone: (415) 688-4484
Fax: (408) 852-4427

Gerald's email address

IR Calendar 



Jenene Thomas Communications
Jenene Thomas
T: 908-938-1475



VStock Transfer, LLC
Allison Niccols
77 Spruce Street
Suite 201
Cedarhurst, N 11516
T: 212-828-8436
F: 646-536-3179


Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline.
  Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
More information
         “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise.

   Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.


 Source Capital Group's 2016 Disruptive Growth & Healthcare Conference - February 10-11, 2016 in New York City.
The Company's presentation will be given on 
Wednesday, February 10, 2016 at 12:30 pm by Gerald E. Commissiong, President & CEO of Amarantus, in the OneMedMarket Venture Track. The presentation will provide an update on the Company's regulatory interactions with FDA.

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
AMBS News: Various Development Advancements for Targeted Treatment Therapies for Rare Diseases & Disorders Lead to Newest Orphan Drug 08:45 AM
AMBS News: Current Report Filing (8-k) 02/09/2016 04:32:07 PM
AMBS News: Statement of Changes in Beneficial Ownership (4) 02/02/2016 10:36:42 AM
AMBS News: Current Report Filing (8-k) 01/29/2016 09:08:11 AM
AMBS News: Current Report Filing (8-k) 01/28/2016 04:24:11 PM
News News Alert: Various Development Advancements for Targeted Treatment Therapies for Rare Diseases & Disorders Lead to Newest Orphan Drug 02/10/2016 08:45:00 AM
#117775  Sticky Note A leg up on multiple sclerosis (and Alzheimer’s) zoomboom 09/18/15 12:03:13 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#122381   Great News, but sellers need to let this Freeblazer 02/10/16 10:13:13 AM
#122380   $AMBS Various Development Advancements for Targeted Treatment Therapies $Pistol Pete$ 02/10/16 10:11:12 AM
#122379   there might be a chance that investors buy Alapis 02/10/16 10:04:24 AM
#122378   Possibly as a way to garnish more attention JJAAMMAANN 02/10/16 09:32:56 AM
#122377   Press release AMBS $$$$$ Dream on, yeah what Shadowfaxin 02/10/16 08:56:00 AM
#122376   Potential, Potential, Potential.....One of these days things are the gipper 02/10/16 08:53:16 AM
#122375   AMBS closed .20 yesterday... bid is .22 on Deagle 02/10/16 08:50:23 AM
#122374   What is the point of having orphan drug Slmiley 02/10/16 08:24:13 AM
#122373   That's good news but didn't they just halt SidVicious 02/10/16 08:04:45 AM
#122372   News: PRESS RELEASES Amarantus Receives Orphan Drug Designation From the SweepsMcGee 02/10/16 07:47:45 AM
#122370   What's happening right now is one of his sante1 02/09/16 08:37:38 PM
#122368   GC has analyzed the price decline and believe Jumpinjackas 02/09/16 08:25:32 PM
#122366   The CEO already put the money out, it's brharris 02/09/16 07:38:41 PM
#122365   GC is doing the same thing the fraudsters ErnieBilco 02/09/16 06:43:32 PM
#122364   So that unicorn going to come or not. mrhg310 02/09/16 06:07:21 PM
#122363   Again the CEO of AMBS acquired the shares Zeusgreek7777 02/09/16 05:34:19 PM
#122362   Back in mid 2014, prior to the UN SidVicious 02/09/16 05:28:59 PM
#122361   it comes to this: what is a lie? christjamin 02/09/16 05:15:50 PM
#122360   hhhhhh.. I love your sarcasm. May The Lord christjamin 02/09/16 05:06:25 PM
#122359   its a way of venting and it's not Zeusgreek7777 02/09/16 04:59:03 PM
#122358   I agree I don't understand why everyone is Jumpinjackas 02/09/16 04:58:07 PM
#122357   I try to treat people the way I christjamin 02/09/16 04:55:44 PM
#122356   This is the first deal to buy back Grundle 02/09/16 04:55:38 PM
#122355   Lol.. hhhhh.. I am pretty sure and very christjamin 02/09/16 04:53:45 PM
#122354   On AMBS payroll maybe ? Zeusgreek7777 02/09/16 04:48:36 PM
#122353   Buying back series E today... Grundle 02/09/16 04:48:36 PM
#122352   Gerald would love to have more "investors" like Jumpinjackas 02/09/16 04:47:03 PM
#122351   Another $230,000 worth of dilution down the pipeline Zeusgreek7777 02/09/16 04:44:51 PM
#122350   Just hang in there. How much of a Jumpinjackas 02/09/16 04:44:13 PM
#122349   More Dilution…After Hour Filling just now. Slmiley 02/09/16 04:39:18 PM
#122348   I am as upset as everybody here. I christjamin 02/09/16 04:36:58 PM
#122347   Lol that is easy . Toxic financing that Zeusgreek7777 02/09/16 04:34:15 PM
#122346   Gerald tell them at the conference that you're JPetroInc 02/09/16 04:33:14 PM
#122345   May my Lord protect me from deceiving or christjamin 02/09/16 04:29:23 PM
#122344   Couldn't resist those offered @ .21! I the gipper 02/09/16 04:27:32 PM
#122343   Are you Gerald? Please be honest. Jumpinjackas 02/09/16 04:14:42 PM
#122342   The CEO can't figure out why the price Jumpinjackas 02/09/16 04:14:07 PM
#122341   What am saying is that AMBS is an Zeusgreek7777 02/09/16 04:10:28 PM
#122339   AMBS is moving on up big things happen Bachbla 02/09/16 03:46:58 PM
#122338   they should all go to jail and then Alapis 02/09/16 03:17:51 PM
#122337   Another presentation but don't expect any outcome from it. leslunier 02/09/16 03:12:44 PM
#122336   You have lost all trust with GC? So christjamin 02/09/16 02:54:35 PM
#122335   So, who is going to be in New JJAAMMAANN 02/09/16 02:53:29 PM
#122334 Kbro13 02/09/16 02:49:21 PM
#122333   99% of penny stocks CEO are the same Zeusgreek7777 02/09/16 02:37:43 PM
#122332   You know, again, all is about perspective. You christjamin 02/09/16 02:31:01 PM
#122331   more to come on that question JPetroInc 02/09/16 02:18:00 PM
#122329   Anyone that has listen to GC is the Zeusgreek7777 02/09/16 02:14:13 PM
#122327   You see, life is all about perspective. You christjamin 02/09/16 02:05:42 PM
#122326   I think Brownie and Gerald have done heck Jumpinjackas 02/09/16 01:57:24 PM